Transdermal Patches Market

The global transdermal patches market in terms of revenue was estimated to be worth $6.2 billion in 2023 and is poised to reach $8.0 billion by 2029, growing at a CAGR of 4.5% from 2023 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The global transdermal patches market is expanding due to a number of factors, including the rising prevalence of chronic illnesses, the expanding use of analgesic patches, technological developments in transdermal patches, and the shift from traditional injections to transdermal patches. However, over the anticipated term, a number of problems, such as medication failure, transdermal drug delivery system recalls, and growing healthcare facility costs, will probably limit market growth to some degree.

Attractive Opportunities in the Transdermal Patches Market

To know about the assumptions considered for the study, Request for Free Sample Report

Transdermal Patches Market Dynamics

Driver: Growing adoption of analgesic patches

The rising use of analgesic patches is indicative of a paradigm shift in pain management techniques, with a focus on non-invasive and focused methods. Analgesic patches have a localized therapeutic effect by delivering a controlled and prolonged release of painkillers through the skin. In addition to improving patient comfort, this technique reduces the possibility of systemic adverse effects from oral painkillers. Analgesic patches are a desirable alternative for those with chronic pain disorders because of their simplicity of administration and prolonged wear period, which both increase patient compliance. Furthermore, the desire for alternate pain management techniques and growing awareness of the opioid epidemic have increased the demand for analgesic patches. Analgesic patch use is increasing as more people realize the advantages of transdermal medication delivery, and these patches are becoming increasingly important in the changing field of pain management.

Restraint: Drug failure and recalls of transdermal drug delivery systems

The complexity and difficulties involved with this novel approach to drug administration are highlighted by the incidence of medication failure and recalls in transdermal drug delivery systems. Transdermal patches provide benefits. However, problems with formulation, adhesive performance, or skin irritation might cause inconsistent drug administration or unfavorable reactions. Problems with the medication itself, the manufacturing process, or the design of the patch can all lead to drug failure, which is the absence of the desired therapeutic effect. Transdermal medication delivery system recalls could happen if there are safety issues, like unanticipated side effects or diminished efficacy. These incidents demonstrate how crucial it is to implement strict quality control procedures during the transdermal patch development and manufacturing process in order to guarantee patient safety and drug efficacy.

Regulatory bodies have a pivotal function in overseeing and addressing these issues, stressing the necessity of constant enhancement in the blueprint and production procedures of transdermal medication delivery systems to reduce the likelihood of medication malfunctions and recalls.

Opportunity: Collaborations between pharmaceutical companies and drug delivery firms

Partnerships between drug delivery companies and pharmaceutical companies in the transdermal patch market have been more common as a result of a common objective to improve patient outcomes and therapeutic effects. Pharmaceutical businesses provide their knowledge of drug pharmacology and their proficiency in drug discovery and formulation. However, medication delivery companies are experts in cutting-edge delivery technologies, such as the creation and production of transdermal patches. These partnerships combine the advantages of both organizations to develop cutting-edge transdermal medication delivery devices. These collaborations frequently lead to the creation of patches with higher levels of adherence, better drug release profiles, and fewer adverse effects. In the end, patients gain from this cooperative approach since it stimulates innovation, expedites the conversion of research into workable solutions, and offers more convenient and efficient transdermal patch options for a variety of therapeutic uses.

Challenge: Technical barriers related to skin irritation and permeability

Technical barriers pertaining to permeability and skin irritation are major obstacles to the development of transdermal patches. The skin, which serves as the main interface for drug absorption, needs to maintain a careful balance between enabling drugs to penetrate it effectively and reducing irritation or negative reactions. It's difficult to get the ideal permeability without sacrificing the integrity of the skin. In order to overcome these obstacles, formulation issues like choosing appropriate permeation enhancers and making sure that the patch is designed correctly are essential. Drug penetration is severely impeded by the skin's natural barrier function, which includes the stratum corneum. To overcome this, creative ways to increase permeability are needed. At the same time, reducing skin irritation necessitates careful patch component selection and patient-specific consideration.

Transdermal Patches Market Ecosystem

The multi-layer drug in adhesive patch holds the largest segment in the transdermal patches industry by drug in adhesive segment in the forecast period.

Given its innovative design and exceptional drug delivery capabilities, the multi-layer drug-in-adhesive segment is expected to hold the largest proportion of the transdermal patches market. This section focuses on adding more layers to the adhesive matrix, which increases the transdermal patch's adaptability and provides more precise control over medication release rates. A comprehensive therapeutic approach for complex medical diseases can be provided by tailoring the distinct layers to release different medications or varied dosages simultaneously. This individualized and adaptable drug delivery system meets a range of patient requirements and adds to the supremacy of the market.

Asia Pacific accounted for the largest CAGR of the global transdermal patches industry, by region in the forecast period.

The transdermal patches market in Asia Pacific is expected to grow at the highest CAGR due to a combination of factors that highlight the region's changing healthcare landscape. Transdermal patches are becoming more and more popular due to the rising incidence of chronic illnesses and rising knowledge of non-invasive medication delivery techniques. The huge and aging population in the area is a major factor in the rising cost of healthcare, which in turn is driving up demand for accessible and patient-friendly treatment choices. The transdermal patch market in Asia Pacific is also expected to rise as a result of breakthroughs in pharmaceutical research and development, rising disposable incomes, and improved healthcare infrastructure. The region's growing market share is a result of government programs that support healthcare access and the rising use of cutting-edge medical technologies.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the transdermal patches Market are Johnson & Johnson (U.S.), Viatris Inc. (U.S.), Hisamatsu Pharmaceuticals Co. Ltd. (Japan), USB S.A. (Belgium), Boehringer Ingelheim International GmbH (Germany), Endo International plc. (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), Agile Therapeutics (U.S.), Bayer AG (Germany), Nitto Denko Corporation (Japan), Cipla Inc. (India),  Iontopatch (U.S.), Medherant Limited (U.K.), AdhexPharma (France), Evernow (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Alvogen Group Inc. (U.S.), Sparsha Pharma International Pvt Ltd (India), Luye Pharma Group (China), Novartis AG (Switzerland), AbbVie Inc. (U.S.), LEAD CHEMICAL Co., Ltd. (Japan), Purdue Pharma L.P (U.S.) and Mundipharma International (U.K.).

Scope of the Transdermal Patches Industry

The research report categorizes the transdermal patches market to forecast revenue and analyze trends in each of the following submarkets:

By Patch Type

• Drug-In-Adhesive
• Matrix Patches
• Reservoir Membrane Patches
• Microneedle Patches
• Iontophoresis Patches
• Vapour Patches

By Adhesive Type

• Acrylic Adhesives
• Silicone Adhesives
• Hydrogel Adhesives
• Other Adhesives

By Application

• Pain Management
• Smoking Cessation
• Hormone Replacement Therapy
• Cardiovascular Disorder
• Central Nervous System Disorder
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End User

• Homecare Settings
• Hospitals And Clinics

By Region

• North America North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (ROLATM)
• Middle East & Africa

Recent Developments of Transdermal Patches Industry

• In July 2023, Industria Macchine Automatiche S.P.A. (Italy) acquired Phoenix Italia S.r.l. (Milano). IMA completed the acquisition of 60% of Phoenix Italia S.r.l. and 100% of its subsidiary Phoenix Tech S.r.l., both companies based in Bareggio (Milano), from its sole shareholder Phoenix Group Holding S.r.l.
• In July 2023, IMA completed the purchase of 70% of Mespic S.r.l. and 100% of its Illinois-based subsidiary, Mespic North America Corporation, from its sole shareholder, Holding FGLG S.r.l..
• In August 2022, SEA Vision Group and Marchesini Group launched the following solutions: the INTEGRA 720V complete robotized blister line, the BL-A525 CW high-speed labeler, and the complete Track & Trace software solution developed by SEA Vision. This is a solution for primary pack serialization and aggregation, comprising a complete range of technologies to print, inspect, and pack serialized blisters and perform aggregation with cartons, all integrated into a 4.0 environment.
• In July 2021. Syntegon Technology GmbH (Germany) and Huhtamaki Group (Finland) collaborated. This collaboration led to the paper-based tablet packaging solution for the pharmaceutical and healthcare industries.
• In March 2021, Syntegon expanded its portfolio for the production of parenteral pharmaceuticals. The company has launched the new SVP Essential, a cost-efficient version of its proven Pharmatec SVP process systems for the production of small-volume liquid pharmaceuticals.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst